Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FR230513 is an experimental small molecule compound belonging to the class of organic compounds known as naphthalenes. It acts as a potent non-nucleoside inhibitor of adenosine deaminase (ADA), with reported high affinity (Ki = 7.7 nM). The compound has been studied in pharmacology and molecular biology for its potential therapeutic applications but has not advanced beyond preclinical or early research stages. Its chemical formula is C18H19N3O2 and it is structurally characterized by a naphthalene moiety linked to an imidazole carboxamide[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FR230513.